by Eric Christianson | Jun 14, 2023 | Infectious Disease and Oncology Medication and Disease State Clinical Pearls
It is that time of the year with creepy/crawly ticks running rampant. This presents an excellent opportunity to go over some of my Lyme disease clinical practice pearls! You never know when these might show up on a board exam! Lyme Disease Clinical Practice Pearls...
by Eric Christianson | May 31, 2023 | Psychiatry and Addiction Medication and Disease State Clinical Pearls
Buspirone is an anti-anxiety medication that can be used for chronic management. I’ll outline some of the most important clinical pearls and share some anecdotal education in this blog post. The Good – Buspirone Clinical Pearls Buspirone is well tolerated...
by Eric Christianson | May 21, 2023 | Gastrointestinal Medication and Disease State Clinical Pearls
So you have a patient who has failed a PPI for GERD. Now what? GERD can be a challenging disease with really bothersome symptoms for patients. I’m going to discuss the options that I’ve seen used in practice with once-daily PPI failure in GERD. Before...
by Eric Christianson | May 17, 2023 | Cardiovascular Medication and Disease State Clinical Pearls
Nitroglycerin and its derivatives have been around for a long time. The identification of nitrate tolerance goes back even prior to 1900. In this post, I’ll discuss the major strategy for nitrate tolerance prevention and some of the issues that may be...
by Eric Christianson | Apr 19, 2023 | Cardiovascular Medication and Disease State Clinical Pearls, Drug Interaction Case Studies and Education For Pharmacists
Beta-blockers are a class of medication that is frequently used for cardiac and cardiovascular purposes. Selectivity and evidence of benefit often guide selection, but one thing that may get overlooked is beta-blocker interactions in relation to CYP enzymes. Not all...
by Eric Christianson | Apr 12, 2023 | Endocrine Medication and Disease State Clinical Pearls
It is theorized that patients who are taking a GLP-1 agonist are at a greater risk for pancreatitis due to the medication causing an increase in stimulation of GLP-1 receptors located in the pancreas. This could lead to an overgrowth or overactivation of pancreatic...
